Histotype Px® Colorectal

Clinical decision support

To best treat cancer, we must understand how the disease will develop. The Histotype Px® Colorectal marker is able to predict the outcome of a patient’s cancer and can guide a more precise treatment for each patient, and thereby avoid over-and undertreatment

Video cover image by: Ketil Jordan

How was the Histotype Px® Colorectal marker developed?

Histotype Px® Colorectal* cancer marker is the most advanced deep convolutional neural network algorithm for determining prognosis in colorectal cancer based on standard histology images. The colorectal algorithm is robust and based on solid ground truth and extensive training and testing with in total 4500 patient samples, 90 million image tiles, from +200 sites in 8 countries. The slides were prepared at several sites, scanned at two sites with two different scanners, ensuring that the test can be used in clinical practice.

*The early version of Histotype Px® Colorectal was named DoMore-V1-CRC (and misc. variations of this description) during development in the DoMore! Project. The CE-IVD certified product Histotype Px® Colorectal is an updated version.

Video cover image: Marian Seiergren

AI and digital pathology will revolutionize the way we treat cancer

CEO and Co-Founder Torbjørn Furuseth presents the company and our lead digital biomarker Histotype Px® Colorectal at the LSX Nordic Congress 2023.

Future Pipeline

DoMore Diagnostics is dedicated to expanding our potential and impact on improving cancer patients’ lives. We are actively pursuing further development and advancing our product portfolio into Prostate cancer and Lung cancer and to determine the Mitotic index for better diagnostics and improved patient care.